Prednisolone
證據等級: L3 | 預測適應症: 10 個
## 藥師評估報告
Prednisolone：從濕疹樣皮膚炎到斑禿 (Alopecia Areata)
一句話總結
Prednisolone 原本用於治療濕疹樣皮膚炎等過敏性或發炎性皮膚疾患。 TxGNN 模型預測它可能對**斑禿 (Alopecia Areata)** 有效， 目前有 **14 個臨床試驗**和 **8 篇文獻**支持這個方向。
快速總覽
| 項目 | 內容 |
|---|---|
| 原適應症 | 濕疹樣皮膚炎、蟲咬傷、尿布疹、皮膚搔癢及過敏性或發炎性皮膚疾患等 |
| 預測新適應症 | alopecia areata、alopecia mucinosa、telogen effluvium、Quinquaud's folliculitis decalvans、alopecia antibody deficiency、hereditary hypotrichosis with recurrent skin vesicles、alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome、atrichia with papular lesions、prolapse of lacrimal gland、Sjogren syndrome |
| TxGNN 預測分數 | 99.99% |
| 證據等級 | L3 |
| 台灣上市 | ✓ 已上市 |
| 許可證數 | 20 張 |
| 建議決策 | Proceed with Guardrails |
預測適應症詳細分析
1. alopecia areata L1 99.99% 主要分析
為什麼這個預測合理？
目前缺乏詳細的作用機轉資料。根據已知資訊，Prednisolone 是一種類固醇藥物，具有抗炎和免疫調節作用。
其成分在治療過敏性和發炎性皮膚疾病中的療效已被證實，機轉上可能適用於斑禿這類自體免疫性疾病。
</p>
</details>
此預測基於藥物的作用機轉，與現有臨床證據方向一致。
臨床試驗
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT04925934 | PHASE2 | COMPLETED | 214 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study... |
| NCT07101471 | N/A | COMPLETED | 296 | A Prospective and Observational Study for Safety and Effectiveness Evaluation of... |
| NCT05162586 | PHASE2 | COMPLETED | 456 | A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel ... |
| NCT03843125 | PHASE3 | TERMINATED | 1147 | A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and ... |
| NCT01017510 | NA | UNKNOWN | 20 | Comparative Study Examining the Effectiveness in Use of a DERMOJET and a Normal ... |
| NCT02031822 | NA | COMPLETED | 40 | Evaluation of Two Ultrasound-guided Techniques for Greater Occipital Nerve Injec... |
| NCT03616912 | PHASE3 | TERMINATED | 830 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of... |
| NCT06759519 | N/A | COMPLETED | 621 | An Observational Multicenter Retrospective-prospective Study of Patients With Ac... |
| NCT04582136 | PHASE3 | ACTIVE_NOT_RECRUITING | 146 | Efficacy and Safety of Sirolimus in Patients With Active Systemic Lupus Erythema... |
| NCT01167946 | PHASE4 | COMPLETED | 42 | Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resi... |
| NCT06046534 | N/A | COMPLETED | 46 | ERYTHRO Retrospective Medical Chart Review Study to Describe the Experience of S... |
| NCT06653556 | EARLY_PHASE1 | RECRUITING | 34 | An Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinet... |
| NCT03616964 | PHASE3 | COMPLETED | 778 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of... |
| NCT03845517 | PHASE2 | COMPLETED | 350 | A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANG... |
| NCT03252587 | PHASE2 | COMPLETED | 363 | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficac... |
| NCT04835441 | PHASE2 | COMPLETED | 76 | A Randomized, Double-blind, Placebo-controlled Study of ALPN-101 in Systemic Lup... |
| NCT01972217 | PHASE2 | COMPLETED | 158 | A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Co... |
| NCT04680637 | PHASE2 | TERMINATED | 168 | A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin... |
相關文獻
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 37870096 | 2023 | Article | The Cochrane database of syste | Treatments for alopecia areata: a network meta-analysis. |
| 30191561 | 2019 | Article | The Australasian journal of de | Systemic treatments for alopecia areata: A systematic review. |
| 37992355 | 2023 | Article | Dermatology practical & concep | The Efficacy and Adverse Effects of Corticosteroid Pulse Therapy in Alopecia Are... |
| 35986630 | 2022 | Article | Dermatologic therapy | Retrospective analysis of methylprednisolone treatment alone and in combination ... |
| 36461625 | 2023 | Article | Pediatric dermatology | Pediatric pulse dose corticosteroid therapy dosing and administration in the tre... |
| 15692475 | 2005 | Article | Journal of the American Academ | Placebo-controlled oral pulse prednisolone therapy in alopecia areata. |
| 28029683 | 2017 | Article | The British journal of dermato | Alopecia areata incognita in Cronkhite-Canada syndrome. |
| 4154458 | 1974 | Article | Proceedings of the Royal Socie | Alopecia areata, vitiligo, scleroderma and ulcerative colitis. |
| 9065564 | 1997 | Article | Neurology | Myasthenia gravis and alopecia areata. |
| 33167077 | 2021 | Article | Journal of cosmetic dermatolog | Co-localization of alopecia areata and lichen planopilaris in a patient receivin... |
| 28140540 | 2017 | Article | Journal der Deutschen Dermatol | Sequential high- and low-dose systemic corticosteroid therapy for severe childho... |
| 21572877 | 2009 | Article | Dermato-endocrinology | Medium-dose prednisolone pulse therapy in alopecia areata. |
| 29963718 | 2018 | Article | The Journal of dermatology | Chronological clinicopathological characterization of rapidly progressive alopec... |
| 28940756 | 2017 | Article | The Journal of dermatology | Efficacy of combining pulse corticotherapy and methotrexate in alopecia areata: ... |
| 25566921 | 2015 | Article | Indian journal of dermatology, | Intravenous methylprednisolone pulse therapy in severe alopecia areata. |
| 30294905 | 2019 | Article | Journal of cosmetic dermatolog | Alteration of serum and tissue tumor necrosis factor alpha levels: A possible me... |
| 13621919 | 1959 | Article | Medical times | Alopecia. |
| 18608727 | 2008 | Article | The Journal of dermatological | Combination therapy of cyclosporine and methylprednisolone on severe alopecia ar... |
| 32779249 | 2020 | Article | Journal of the European Academ | Utility of azathioprine, methotrexate and cyclosporine as steroid-sparing agents... |
| 14157908 | 1963 | Article | Bulletin de la Societe francai | [ALOPECIA AREATA AND CORTICOTHERAPY]. |
2. alopecia mucinosa L4 99.99%
相關文獻（5 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 40657655 | 2024 | Article | Acta dermatovenerologica Croat | A Case of Idiopathic Follicular Mucinosis Treated Successfully with Cyclosporine... |
| 10215785 | 1999 | Article | The British journal of dermato | Pilotropic mycosis fungoides presenting with multiple cysts, comedones and alope... |
| 9310735 | 1997 | Article | Dermatology (Basel, Switzerlan | Follicular mucinosis and systemic lupus erythematosus. |
| 20141606 | 2010 | Article | Veterinary dermatology | Canine cutaneous epitheliotropic T-cell lymphoma: a review of 30 cases. |
| 4278795 | 1974 | Article | Zeitschrift fur Hautkrankheite | [Follicular mucinosis and large area, partly lichenoid, partly sclerodermiform g... |
3. telogen effluvium L4 99.98%
相關文獻（1 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 31056741 | 2019 | Article | The Australasian journal of de | Alopecia in Cronkhite-Canada syndrome: Is it truly telogen effluvium? |
4. Quinquaud's folliculitis decalvans L4 99.98%
5. alopecia antibody deficiency L4 99.98%
相關文獻（3 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 36117202 | 2022 | Article | Allergy, asthma, and clinical | Systemic lupus erythematosus with various clinical manifestations in a patient w... |
| 30099593 | 2018 | Article | Rheumatology international | Lupus anticoagulant hypoprothrombinemia syndrome associated with systemic lupus ... |
| 19433284 | 2009 | Article | Pediatric neurology | Rasmussen syndrome combined with IgA deficiency and membranous nephropathy. |
6. hereditary hypotrichosis with recurrent skin vesicles L5 99.98%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
7. alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome L5 99.98%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
8. atrichia with papular lesions L5 99.94%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
9. prolapse of lacrimal gland L5 99.94%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
10. idiopathic steroid-sensitive nephrotic syndrome L1 99.86%
臨床試驗（8 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT07233330 | PHASE2 | NOT_YET_RECRUITING | 10 | Obinutuzumab Treatment in Frequently Relapsing and Rituximab-Dependent Idiopathi... |
| NCT04783675 | PHASE2 | COMPLETED | 44 | Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Ne... |
| NCT04818723 | NA | COMPLETED | 106 | Role of Montelukast in Preventing Relapse in Childhood Idiopathic Nephrotic Synd... |
| NCT05044169 | NA | UNKNOWN | 83 | Efficacy and Safety of Broncho-Vaxom in Reducing Recurrence in Children With Ste... |
| NCT06635720 | PHASE3 | RECRUITING | 50 | REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE): a Pil... |
| NCT07151456 | PHASE4 | NOT_YET_RECRUITING | 224 | Short-term vs Conventional Glucocorticoid Therapy for the Treatment of the Initi... |
| NCT06792448 | N/A | NOT_YET_RECRUITING | 350 | Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Tr... |
| NCT05627557 | PHASE3 | ACTIVE_NOT_RECRUITING | 85 | A Phase III, International, Multicenter, Randomised Open Label Study to Evaluate... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 33478977 | 2021 | Article | Clinical journal of the Americ | Steroid Regimen for Children with Nephrotic Syndrome Relapse. |
| 40337980 | 2025 | Article | The Cochrane database of syste | Interventions for idiopathic steroid-resistant nephrotic syndrome in children. |
| 30342869 | 2018 | Article | The Lancet. Child & adolescent | Management of steroid-resistant nephrotic syndrome in children and adolescents. |
| 27726125 | 2016 | Article | The Cochrane database of syste | Interventions for idiopathic steroid-resistant nephrotic syndrome in children. |
| 34925975 | 2021 | Article | Cureus | Management of Steroid-Resistant Nephrotic Syndrome in Children. |
| 29869116 | 2019 | Article | Pediatric nephrology (Berlin, | Treating the idiopathic nephrotic syndrome: are steroids the answer? |
| 39630311 | 2025 | Article | Clinical and experimental neph | MicroRNAs in idiopathic childhood nephrotic syndrome. |
| 36179014 | 2023 | Article | Jornal brasileiro de nefrologi | Outcomes of children with idiopathic steroid resistant nephrotic syndrome: a sin... |
| 38599658 | 2024 | Article | British journal of clinical ph | Saliva monitoring of prednisolone in children with first onset steroid-sensitive... |
| 27719329 | 2017 | Article | British journal of biomedical | ABCB1 polymorphisms and steroid treatment in children with idiopathic nephrotic ... |
| 20686809 | 2010 | Article | Clinical and experimental neph | Th2 cells predominate in idiopathic steroid-sensitive nephrotic syndrome. |
| 19179716 | 2009 | Article | Indian pediatrics | Management of steroid resistant nephrotic syndrome. |
| 17225845 | 2006 | Article | Journal of the National Medica | Childhood nephrotic syndrome: change in pattern and response to steroids. |
| 28544686 | 2017 | Article | Pediatrics international : off | Regulatory T cells and CTLA-4 in idiopathic nephrotic syndrome. |
| 28748888 | 2017 | Article | Saudi journal of kidney diseas | Childhood idiopathic steroid-resistant nephrotic syndrome at a Single Center in ... |
| 33070945 | 2021 | Article | Medicina clinica | Efficacy and safety of rituximab for childhood refractory nephrotic syndrome: A ... |
| 38642993 | 2024 | Article | Kidney international | Levamisole in childhood idiopathic nephrotic syndrome: new promises, and advocac... |
| 26329674 | 2015 | Article | Renal failure | Intermittent high-volume hemofiltration promotes remission in steroid-resistant ... |
| 27108294 | 2017 | Article | Clinical and experimental neph | Long-term efficacy and safety of common steroid-sparing agents in idiopathic nep... |
| 21558430 | 2012 | Article | Nephrology, dialysis, transpla | Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of ... |
資料來源：DDInter 2.0（原文內容請參閱該網站）
**Latent Tuberculosis** 🟡 Moderate
- 需定期監測。
**Fibrosis** 🟡 Moderate
- 需密切監測。可能需要調整劑量。
**Psychotic Disorders** 🟡 Moderate
- 需定期監測。
**糖尿病** 🟡 Moderate
- 需密切監測。風險包括：高血糖。
**Water-Electrolyte Imbalance** 🟡 Moderate
- 應謹慎使用本藥物。風險包括：癲癇發作。
**Water-Electrolyte Imbalance** 🟡 Moderate
- 注意事項：Corticosteroids may cause hypernatremia, hypokalemia, fluid retention, and elevation in blood pressure...
**Peptic Ulcer Perforation** 🟡 Moderate
- 應避免使用本藥物。風險包括：出血、感染。
**Cushing Syndrome** 🟡 Moderate
- 注意事項：Corticosteroids mimic the effects of endogenous cortisol and aldosterone...
**Hyperlipidemias** 🟡 Moderate
- 需定期監測。
**甲狀腺機能低下** 🟡 Moderate
- 需密切監測。可能需要調整劑量。
**肝臟疾病** 🟡 Moderate
- 可能需要調整劑量。
**Myocardial Infarction** 🟡 Moderate
- 應謹慎使用本藥物。
**重症肌無力** 🟡 Moderate
- 應謹慎使用本藥物。必要時應停止治療。
**Muscular Diseases** 🟡 Moderate
- 可能有嚴重不良反應。
**Keratitis, Herpetic** 🟡 Moderate
- 不建議使用本藥物。
**Toxic Optic Neuropathy** 🟡 Moderate
- 注意事項：Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma...
**骨質疏鬆症** 🟡 Moderate
- 注意事項：Corticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss durin...
**消化性潰瘍** 🟡 Moderate
- 應避免使用本藥物。風險包括：出血。
**Scleroderma, Localized** 🟡 Moderate
- 注意事項：In patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in reni...
**Strongyloidiasis** 🟡 Moderate
- 應謹慎使用本藥物。風險包括：感染。可能有致命風險。
**Thromboembolism** 🟡 Moderate
- 風險包括：血栓。
**Infections** 🟢 Minor
- 不應使用本藥物。風險包括：感染。可能危及生命。
**Premature Birth** 🟢 Minor
- 本藥物在此情況下禁用。可能有致命風險。特別注意族群：兒童。
## 結論與下一步
**決策：Proceed with Guardrails**
**理由：**
Prednisolone 在斑禿的治療中已有多個臨床試驗和文獻支持，顯示其可能的療效和安全性。
**若要推進需要：**
- 進一步的機轉研究以確認其在斑禿中的作用機制
- 特定族群的安全性監測計畫
---
## 相關藥物報告
- [Human Immunoglobulin G](/drugs/human_immunoglobulin_g/) - 證據等級 L3
- [Durvalumab](/drugs/durvalumab/) - 證據等級 L3
- [Lornoxicam](/drugs/lornoxicam/) - 證據等級 L3
- [Dupilumab](/drugs/dupilumab/) - 證據等級 L3
- [Interferon Beta-1B](/drugs/interferon_beta-1b/) - 證據等級 L3
---
用 AI 幫我深入分析
想進一步了解這個藥物的老藥新用潛力嗎？點擊下方按鈕，直接開啟 AI 助手進行分析。
Claude：點擊後會複製提問並開啟新視窗，請按 Ctrl+V（Mac: Cmd+V）貼上
ChatGPT：點擊後直接開啟並自動帶入提問
免責聲明
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
歡迎分享您對本報告的看法、補充資訊或提出問題。討論內容會同步到 GitHub Discussions。 需要 GitHub 帳號才能留言。